ProfileGDS5678 / 1445433_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 32% 32% 32% 32% 35% 35% 32% 31% 32% 32% 32% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7611132
GSM967853U87-EV human glioblastoma xenograft - Control 22.7299132
GSM967854U87-EV human glioblastoma xenograft - Control 32.736432
GSM967855U87-EV human glioblastoma xenograft - Control 42.6851832
GSM967856U87-EV human glioblastoma xenograft - Control 52.6777832
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8796235
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8497335
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7112532
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6827631
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7126432
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7168932
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7061432
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7407832
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7317932